Literature DB >> 32583675

Association of PON1 gene polymorphisms and enzymatic activity with risk of coronary artery disease.

Charuta Godbole1, Saket Thaker1, Prafulla Kerkar2, Milind Nadkar3, Nithya Gogtay1, Urmila Thatte1.   

Abstract

Background: The present case-control study evaluated the association of PON1 gene polymorphisms and enzyme activity in the western Indian population. Materials & methods: Angiographically proven coronary artery disease (CAD) formed the cases. PON1 polymorphisms (Q192R, L55M) and enzymatic activity (paraoxonase) were assessed.
Results:  A total of 502 participants (251 per group) were studied. PON1 Q192R and L55M polymorphisms were not associated with the risk of CAD. Notably, a weak association was observed between Q192R polymorphisms and the risk of CAD. CAD patients had significantly lower PON1 enzymatic activity (U/L) as compared with the controls regardless of the genotype.
Conclusion: Low serum PON1 activity was confirmed to be an independent predictor for the risk of CAD.

Entities:  

Keywords:  atherosclerosis; paraoxonase; polymorphism

Mesh:

Substances:

Year:  2020        PMID: 32583675     DOI: 10.2217/fca-2020-0028

Source DB:  PubMed          Journal:  Future Cardiol        ISSN: 1479-6678


  3 in total

1.  The Role of Paraoxonase 1 (PON1) Gene Polymorphisms in Coronary Artery Disease: A Systematic Review and Meta-Analysis.

Authors:  Sana Ashiq; Kanwal Ashiq
Journal:  Biochem Genet       Date:  2021-02-18       Impact factor: 1.890

Review 2.  The Relevance of Noncoding DNA Variations of Paraoxonase Gene Cluster in Atherosclerosis-Related Diseases.

Authors:  Anna Wysocka; Agnieszka Zwolak
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

Review 3.  Paraoxonase-1 (PON-1) Arylesterase Activity Levels in Patients with Coronary Artery Disease: A Meta-Analysis.

Authors:  Marco Zuin; Alessandro Trentini; Judit Marsillach; Andrea D'Amuri; Cristina Bosi; Loris Roncon; Angelina Passaro; Giovanni Zuliani; Mike Mackness; Carlo Cervellati
Journal:  Dis Markers       Date:  2022-03-10       Impact factor: 3.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.